Selected article for: "antiviral therapy and clinical management"

Author: Franzetti, Marco; Pozzetti, Ugo; Carugati, Manuela; Pandolfo, Alessandro; Molteni, Chiara; Faccioli, Paolo; Castaldo, Gioacchino; Longoni, Ernesto; Ormas, Valentina; Iemoli, Enrico; Piconi, Stefania
Title: Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe Coronavirus disease 2019: A case report
  • Cord-id: fybbnn46
  • Document date: 2020_5_16
  • ID: fybbnn46
    Snippet: Abstract We report the first successful treatment with the IL-1 receptor antagonist anakinra, in association with the most promising and available antiviral therapy, of a severe case of novel coronavirus disease 2019 (COVID-19). We describe the diagnosis, clinical course, and management of the case, including the respiratory failure at presentation, the progression to a scenario characterized by profound inflammatory dysregulation similar to that observed during macrophage activation syndrome, a
    Document: Abstract We report the first successful treatment with the IL-1 receptor antagonist anakinra, in association with the most promising and available antiviral therapy, of a severe case of novel coronavirus disease 2019 (COVID-19). We describe the diagnosis, clinical course, and management of the case, including the respiratory failure at presentation, the progression to a scenario characterized by profound inflammatory dysregulation similar to that observed during macrophage activation syndrome, and the clinical improvement after treatment with the IL-1 receptor antagonist anakinra. This case highlights the high tolerability and the interesting immunomodulatory profile of the IL-1 receptor antagonist anakinra in the setting of severe COVID-19 associated with remdesivir therapy. Further studies are needed to confirm the safety and efficacy of this combination strategy in the treatment of this emerging infection.

    Search related documents:
    Co phrase search for related documents
    • long viral shedding and low expression: 1
    • long viral shedding and lung consolidation: 1
    • long viral shedding and lung involvement: 1
    • lopinavir ritonavir and lung consolidation: 1, 2
    • lopinavir ritonavir and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • lopinavir ritonavir and lung involvement: 1, 2, 3, 4, 5
    • lopinavir ritonavir and macrophage activation: 1, 2, 3
    • lopinavir ritonavir and macrophage activation syndrome: 1, 2, 3
    • low expression and lung disease: 1, 2, 3, 4, 5
    • low expression and macrophage activation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • low expression and macrophage activation syndrome: 1, 2, 3, 4
    • lung disease and macrophage activation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • lung disease and macrophage activation syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • lung disease severity and macrophage activation: 1
    • lung involvement and macrophage activation: 1, 2, 3, 4, 5, 6